Clinical Trials Sponsored by Ontario Cancer Research Network

Total 578 results

SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Malignant Solid Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)

Atypical Hyperplasia of the Breast | Lobular Breast Carcinoma In Situ | Pleomorphic Lobular Breast Carcinoma In Situ

United States, Guam
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study of miRNA 371 in Patients With Germ Cell Tumors

Seminoma | Germ Cell Tumor | Metachronous Malignant Neoplasm | Stage I Testicular Cancer AJCC v8 | Stage IA Testicular Cancer AJCC v8 | Stage IB Testicular Cancer AJCC v8 | Stage IS Testicular Cancer AJCC v8

Canada, United States, Guam
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell Carcinoma

United States, Canada, Korea, Republic of, Mexico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Elevated CA15-3 or CEA or CA27-29

United States, Puerto Rico, Guam
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostatic Adenocarcinoma | Castration Levels of Testosterone

United States, Switzerland, Mexico, Chile, Colombia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Cardiotoxicity | Recurrent Breast Carcinoma | HER2/Neu Positive | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7

United States, Korea, Republic of, Puerto Rico, Saudi Arabia
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Small Cell Squamous Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Recurrent Lung Adenocarcinoma | Loss of Heterozygosity | Recurrent... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

Malignant Solid Neoplasm | Hepatitis B Infection

United States, Guam
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Unresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors

Rectal Carcinoma | Rectosigmoid Carcinoma

United States, Guam
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Bladder Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Prostate Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Stage II Bladder Cancer AJCC v8 | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall | Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

United States
HamesNet Research Network
Pearl Network; Eisenhower Army Medical Center

Unknown

Eisenhower's Alternative Speculum Examination (EASE)

Papanicolaou Smear

United States
Ottawa Hospital Research Institute
Ontario HIV Treatment Network; Public Health Agency of Canada (PHAC); CIHR Canadian...

Completed

Influenza Vaccine in HIV

HIV | Influenza

Canada
Matthew Milowsky, MD
Hoosier Cancer Research Network; Bladder Cancer Advocacy Network (BCAN®)

Completed

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch

Bladder Cancer | Urothelial Carcinoma | Urethral Cancer | Cancer of the Ureter

United States
Ottawa Hospital Research Institute
Ontario Institute for Cancer Research; Intensity Therapeutics, Inc.

Recruiting

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

Breast Cancer

Canada
Hoosier Cancer Research Network
Clovis Oncology, Inc.

Completed

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Breast Cancer

United States
Hoosier Cancer Research Network
Bristol-Myers Squibb

Completed

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

Transitional Cell Carcinoma of the Bladder

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC; Canadian Institutes of Health Research (CIHR); Ontario... and other collaborators

Terminated

The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men (HPV-SAVE)

Anal Cancer | Human Papillomavirus | Anal Dysplasia

Canada
Dipenkumar Modi
Genmab

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Relapsed Cancer | Refractory Cancer | Large Cell Lymphoma, Diffuse

United States
Matthew Galsky
AstraZeneca

Active, not recruiting

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

Urothelial Carcinoma

United States
Hoosier Cancer Research Network
Bristol-Myers Squibb

Completed

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Urothelial Carcinoma

United States
Guru Sonpavde
Pfizer; Hoosier Cancer Research Network

Withdrawn

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Kidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney Carcinoma

United States
Hoosier Cancer Research Network
Pfizer; Novartis Pharmaceuticals

Completed

Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

Colorectal Cancer

United States
Devalingam Mahalingam
Amgen

Withdrawn

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer | KRAS P.G12C

United States
Gregory A. Dekaban
University of Western Ontario, Canada; Ontario Institute for Cancer Research

Unknown

Tracking Peripheral Blood Mononuclear Cells With Fluorine MRI (TRACK)

Adverse Reaction to Diagnostic Agents and Kits Nos

Canada
University of Nottingham
AstraZeneca; Cancer Research UK; National Cancer Research Network

Completed

AKT Inhibitor in Oestrogen Positive Breast Cancer (STAKT)

Invasive Breast Cancer

United Kingdom
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Research Alliance

Completed

Accelerated Radiotherapy Outcomes in Women

Breast Cancer

Canada
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Research Alliance

Completed

Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer "DELTA STUDY"

Breast Cancer | Lymphedema

Canada
Hoosier Cancer Research Network
Novartis Pharmaceuticals; Walther Cancer Institute

Terminated

Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma

Multiple Myeloma

United States
Hoosier Cancer Research Network
Genentech, Inc.; Walther Cancer Institute

Completed

A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Hoosier Cancer Research Network
Novartis Pharmaceuticals; Walther Cancer Institute

Terminated

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
CERN Foundation - Collaborative Ependymoma Research Network

Completed

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Brain Cancer | Pediatric Cancers

United States
H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer Action Network

Recruiting

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Comprehensive Cancer Network

Withdrawn

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Liver Cancer | HepatoCellular Carcinoma | Unresectable HepatoCellular Carcinoma

United States
Bruyere Research Institute
The Ottawa Hospital; Ontario Ministry of Health and Long Term Care; Ontario Medical... and other collaborators

Completed

Building Capacity for Specialized Services Through eConsultation (eConsult)

Health Services Research

Canada
Rachel Sanborn
AstraZeneca; Providence Cancer Center, Earle A. Chiles Research Institute

Active, not recruiting

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Lung Cancer | Non-small Cell Carcinoma

United States
Joshua Palmer
Genentech, Inc.

Recruiting

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE)

NSCLC | Lung Cancer | Brain Metastases

United States
Oana Danciu
Novartis Pharmaceuticals

Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR)

HER2-negative Breast Cancer | Locoregional Recurrence | Hormone Receptor-positive Breast Cancer

United States
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Carcinoma, Unspecified Site

United States
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Costantine Albany
Tesaro, Inc.

Withdrawn

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Germ Cell Tumor
Noah Hahn, M.D.
Pfizer; Hoosier Cancer Research Network

Terminated

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Transitional Cell Carcinoma of the Bladder

United States, United Kingdom
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Germ Cell Tumors

United States
Lawrence Einhorn
Hoosier Cancer Research Network; Celgene Corporation

Completed

Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies

Lung Cancer

United States

Clinical Trials Sponsored by Ontario Cancer Research Network

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations